Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2018
At a glance
- Drugs CMB 305 (Primary) ; Cyclophosphamide (Primary) ; Interleukin-2 (Primary) ; LV 305 (Primary) ; T lymphocyte cell therapies (Primary)
- Indications Liposarcoma; Sarcoma; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
- 14 Sep 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 02 Jul 2018 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.